JP2008521426A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521426A5
JP2008521426A5 JP2007543912A JP2007543912A JP2008521426A5 JP 2008521426 A5 JP2008521426 A5 JP 2008521426A5 JP 2007543912 A JP2007543912 A JP 2007543912A JP 2007543912 A JP2007543912 A JP 2007543912A JP 2008521426 A5 JP2008521426 A5 JP 2008521426A5
Authority
JP
Japan
Prior art keywords
seq
domain
plad
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521426A (ja
Filing date
Publication date
Priority claimed from PCT/GB2005/002163 external-priority patent/WO2005118642A2/en
Priority claimed from PCT/GB2005/004319 external-priority patent/WO2006051288A2/en
Application filed filed Critical
Priority claimed from PCT/GB2005/004603 external-priority patent/WO2006059110A2/en
Publication of JP2008521426A publication Critical patent/JP2008521426A/ja
Publication of JP2008521426A5 publication Critical patent/JP2008521426A5/ja
Pending legal-status Critical Current

Links

JP2007543912A 2004-12-02 2005-12-01 ドメイン抗体への複合体化により血清半減期が延長されたｐｌａｄドメインペプチド Pending JP2008521426A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63236104P 2004-12-02 2004-12-02
PCT/GB2005/002163 WO2005118642A2 (en) 2004-06-01 2005-05-31 Bispecific fusion antibodies with enhanced serum half-life
PCT/GB2005/004319 WO2006051288A2 (en) 2004-11-10 2005-11-10 Ligands that enhance endogenous compounds
PCT/GB2005/004603 WO2006059110A2 (en) 2004-12-02 2005-12-01 Plad domain peptides with increased serum half life due to conjugation to domain antibodies

Publications (2)

Publication Number Publication Date
JP2008521426A JP2008521426A (ja) 2008-06-26
JP2008521426A5 true JP2008521426A5 (enExample) 2008-12-11

Family

ID=38792261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543912A Pending JP2008521426A (ja) 2004-12-02 2005-12-01 ドメイン抗体への複合体化により血清半減期が延長されたｐｌａｄドメインペプチド

Country Status (14)

Country Link
US (1) US20090111745A1 (enExample)
EP (1) EP2024396A2 (enExample)
JP (1) JP2008521426A (enExample)
KR (1) KR20070099584A (enExample)
CN (1) CN101111522A (enExample)
AU (1) AU2005311103A1 (enExample)
BR (1) BRPI0518762A2 (enExample)
CA (1) CA2589802A1 (enExample)
IL (1) IL183451A0 (enExample)
MX (1) MX2007006602A (enExample)
NO (1) NO20072670L (enExample)
RU (2) RU2411957C2 (enExample)
WO (1) WO2006059110A2 (enExample)
ZA (3) ZA200704431B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263788A2 (en) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2613494A1 (en) * 2005-06-24 2007-01-04 Michael Lenardo Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (plad) of tumor necrosis factor receptors
WO2007146163A2 (en) * 2006-06-09 2007-12-21 Welson Pharmaceuticals, Inc. Fc-fusion proteins with reduced fc-mediated effector activities
US8460647B2 (en) 2007-04-20 2013-06-11 Amgen Inc. Pre-ligand assembly domain of the IL-17 receptor
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
EP2535350B1 (en) * 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
CN105061593B (zh) 2009-02-19 2018-08-03 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
JP2012532619A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
EP2523686A2 (en) 2010-01-14 2012-11-21 Glaxo Group Limited Liver targeting domain antibodies
HRP20230776T1 (hr) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
LT2609118T (lt) 2010-08-23 2017-04-25 Board Of Regents, The University Of Texas System Anti-ox40 antikūnai ir jų panaudojimo būdai
SG10201606218WA (en) * 2011-07-29 2016-09-29 Eleven Biotherapeutics Inc Purified Proteins
US20130129727A1 (en) * 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
US9273092B2 (en) 2011-12-23 2016-03-01 RioGin LLC Selective binding compounds
US20130165628A1 (en) * 2011-12-23 2013-06-27 Sri International Double Binding Constructs
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
BR112016004355A2 (pt) 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
PT3583125T (pt) * 2017-02-16 2025-04-04 Sonnet Biotherapeutics Inc Proteínas de fusão ao domínio de ligação à albumina
CN112409480B (zh) * 2019-08-20 2024-08-27 四川科伦博泰生物医药股份有限公司 结合血清白蛋白的蛋白及其用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
US12410252B2 (en) 2021-09-10 2025-09-09 Trustees Of Tufts College Anti-PD-1 immunoglobulin polypeptides and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US6479632B1 (en) * 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5359037A (en) * 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) * 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
JPH03164179A (ja) * 1989-04-21 1991-07-16 Boehringer Ingelheim Internatl Gmbh Ｔｎｆレセプター、ｔｎｆ結合たん白質およびこれらをコードするｄｎａ
US6262239B1 (en) * 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
AU636608B2 (en) * 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US7608681B2 (en) * 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU2001233212A1 (en) * 2000-02-02 2001-08-14 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
EP1263788A2 (en) * 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
JP4303105B2 (ja) * 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
WO2003013573A1 (en) * 2001-08-10 2003-02-20 Epix Medical, Inc. Polypeptide conjugates with extended circulating half-lives
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
KR20070084069A (ko) * 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
RU2007119989A (ru) Композиции, слитые конструкции и конъюгаты plad домена
TWI608015B (zh) 具有組織標的功能的抗發炎分子
JP2020508329A5 (enExample)
KR101281208B1 (ko) 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질
US8193322B2 (en) Methods for generating monovalent IgG
JP2019137675A5 (enExample)
JP2015509097A5 (enExample)
JP2008512988A5 (enExample)
TWI886164B (zh) 1價ccap生成物之製造方法
JP2021502810A5 (enExample)
JP2021508449A5 (enExample)
JP2017529059A5 (enExample)
JP2006511516A5 (enExample)
JP2008508882A5 (enExample)
JP2016524592A5 (enExample)
CN109796534B (zh) 抗il-17抗体/tnfr ecd融合蛋白及其用途
JP2019507589A5 (enExample)
JPH04507195A (ja) 腫瘍壊死因子結合リガンド
JP2010502208A (ja) 半減期の長い血清アルブミン結合タンパク質
JP2014519830A5 (enExample)
JP2017529067A (ja) Ｃｄ３結合ドメイン
JP2009517069A5 (enExample)
JP6469012B2 (ja) インターロイキン−６に対する抗体およびその使用
JP2010524849A5 (enExample)
JP2012527875A5 (enExample)